Compugen News

News

Ticker

CGEN

ISIN

IL0010852080

Przychody Zysk netto C/Z C/P EBIT Dywidenda Transakcje członków zarządu Akcje Kapitalizacja rynkowa Zadłużenie Zobowiązania Kapitał własny AAQS Pracownicy ROE ROA ROCE News Dokumenty

Compugen Wiadomości Eulerpool

Wiadomości akcji Compugen

Compugen jest monitorowana przez dziennikarzy i inwestorów na całym świecie. Zbieramy tutaj najnowsze wiadomości Compugen.

2 marca·
SeekingAlpha
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement
2 marca·
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
2 marca·
SeekingAlpha
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
2 marca·
Benzinga
Compugen Says It Is On Track To Have MAIA-Ovarian Interim Analysis In Q1 2027
2 marca·
Benzinga
Earnings Breakdown: Compugen Q4
2 marca·
Benzinga
Compugen Q4 EPS $0.60 Beats $0.05 Estimate, Sales $67.332M Beat $1.357M Estimate
2 marca·
Benzinga
Earnings Scheduled For March 2, 2026
27 lutego·
Benzinga
Uncovering Potential: Compugen's Earnings Preview
26 lutego·
Yahoo
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
26 lutego·
Yahoo
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
19 lutego·
Yahoo
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
19 lutego·
Yahoo
Compugen to Participate in Upcoming Investor Conferences
17 lutego·
Yahoo
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
12 lutego·
Yahoo
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
17 grudnia·
Benzinga
Compugen Agrees With AstraZeneca To Monetize Portion Of Compugen's Rilvegostomig Future Royalties
10 listopada·
Yahoo
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
10 listopada·
Yahoo
Compugen Reports Third Quarter 2025 Results
10 listopada·
SeekingAlpha
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
9 sierpnia·
Yahoo
Need To Know: Analysts Just Made A Substantial Cut To Their Compugen Ltd. (NASDAQ:CGEN) Estimates
8 sierpnia·
SeekingAlpha
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Komunikaty prasowe akcji Compugen

Compugen regularnie publikuje wiadomości na stronie internetowej firmy, które są istotne dla inwestorów.

8 sierpnia•
Compugen
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
4 sierpnia•
Compugen
Compugen Reports Second Quarter 2022 Results
21 lipca•
Compugen
Compugen to Release Second Quarter Results on Thursday, August 4, 2022
27 czerwca•
Compugen
Compugen to Present at Upcoming Industry Conferences
1 czerwca•
Compugen
Compugen to Present at Upcoming Investor Conferences
16 maja•
Compugen
Compugen Reports First Quarter 2022 Results
10 maja•
Compugen
Compugen Announces CFO Departure
2 maja•
Compugen
Compugen to Release First Quarter 2022 on Monday, May 16, 2022
21 marca•
Compugen
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
14 marca•
Compugen
Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium
9 marca•
Compugen
Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference
9 marca•
Compugen
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma
24 lutego•
Compugen
Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
24 lutego•
Compugen
Compugen Reports Fourth Quarter and Full Year 2021 Results
10 lutego•
Compugen
Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022
9 lutego•
Compugen
Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
18 stycznia•
Compugen
Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies
9 grudnia•
Compugen
Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
12 listopada•
Compugen
Compugen Reports Third Quarter 2021 Results
8 listopada•
Compugen
Compugen to Present at Upcoming Investor Conferences
26 października•
Compugen
Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021
1 października•
Compugen
Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021
14 września•
Compugen
Compugen to Present at the Cantor Global Healthcare Conference
26 sierpnia•
Compugen
Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
19 sierpnia•
Compugen
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
28 lipca•
Compugen
Compugen Reports Second Quarter 2021 Results
19 lipca•
Compugen
Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207
15 lipca•
Compugen
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
14 lipca•
Compugen
Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021
30 czerwca•
Compugen
Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

Compugen News 2026

Ta strona zawiera wszystkie bieżące wiadomości, analizy i komunikaty prasowe akcji Compugen (CGEN, ISIN: IL0010852080). Obejmuje to wiadomości Eulerpool, analizy firm i oficjalne komunikaty prasowe. Dane są regularnie aktualizowane, aby zapewnić inwestorom pełny przegląd najnowszych osiągnięć Compugen.

Compugen Akcja

Compugen Compugen Ltd to izraelska firma biotechnologiczna, która skupia się na rozwoju terapeutów i produktów diagnostycznych. Firma została założona w 1993 roku i ma swoją siedzibę w Tel Awiwie.